Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-03-27 | Viking Therapeutics, Inc. | Mancini Marianna
(Chief Operating Officer) |
F | Common Stock, par value $0.00001 per share | D | 16610 | $83.34 - $83.34 | $1,384,277 |
| 2024-03-27 | Viking Therapeutics, Inc. | Mancini Marianna
(Chief Operating Officer) |
A | Common Stock, par value $0.00001 per share | A | 31667 | $0.00 - $0.00 | $0 |
| 2024-03-27 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
F | Common Stock, par value $0.00001 per share | D | 153948 | $83.34 - $83.34 | $12,830,026 |
| 2024-03-27 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
A | Common Stock, par value $0.00001 per share | A | 221667 | $0.00 - $0.00 | $0 |
| 2024-03-27 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
F | Common Stock, par value $0.00001 per share | D | 16610 | $83.34 - $83.34 | $1,384,277 |
| 2024-03-27 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
A | Common Stock, par value $0.00001 per share | A | 31667 | $0.00 - $0.00 | $0 |
| 2024-03-01 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
F | Common Stock, par value $0.00001 per share | D | 162815 | $85.22 - $85.22 | $13,875,094 |
| 2024-03-01 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
A | Common Stock, par value $0.00001 per share | A | 221667 | $0.00 - $0.00 | $0 |
| 2024-03-01 | Viking Therapeutics, Inc. | Mancini Marianna
(Chief Operating Officer) |
F | Common Stock, par value $0.00001 per share | D | 16958 | $85.22 - $85.22 | $1,445,160 |
| 2024-03-01 | Viking Therapeutics, Inc. | Mancini Marianna
(Chief Operating Officer) |
A | Common Stock, par value $0.00001 per share | A | 31667 | $0.00 - $0.00 | $0 |
| 2024-03-01 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
F | Common Stock, par value $0.00001 per share | D | 20093 | $85.22 - $85.22 | $1,712,325 |
| 2024-03-01 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
A | Common Stock, par value $0.00001 per share | A | 31667 | $0.00 - $0.00 | $0 |
| 2024-02-09 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
S | Common Stock, par value $0.00001 per share | D | 45000 | $29.90 - $29.90 | $1,345,500 |
| 2024-02-08 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
S | Common Stock, par value $0.00001 per share | D | 269079 | $25.75 - $28.90 | $7,230,784 |
| 2024-02-08 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
M | Common Stock, par value $0.00001 per share | A | 189079 | $1.23 - $4.65 | $711,367 |
| 2024-02-08 | Viking Therapeutics, Inc. | Rouan Sarah Kathryn
(Director) |
S | Common Stock, par value $0.00001 per share | D | 25000 | $28.05 - $28.05 | $701,250 |
| 2024-02-08 | Viking Therapeutics, Inc. | Rouan Sarah Kathryn
(Director) |
M | Common Stock, par value $0.00001 per share | A | 25000 | $8.32 - $8.32 | $208,000 |
| 2024-01-31 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
S | Common Stock, par value $0.00001 per share | D | 85000 | $24.45 - $24.95 | $2,100,750 |
| 2024-01-31 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
M | Common Stock, par value $0.00001 per share | A | 85000 | $1.23 - $1.23 | $104,550 |
| 2024-01-30 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
S | Common Stock, par value $0.00001 per share | D | 35000 | $23.95 - $23.95 | $838,250 |
| 2024-01-30 | Viking Therapeutics, Inc. | Lian Brian
(President & CEO) |
M | Common Stock, par value $0.00001 per share | A | 35000 | $1.23 - $1.23 | $43,050 |
| 2024-01-19 | Viking Therapeutics, Inc. | Rouan Sarah Kathryn
(Director) |
S | Common Stock, par value $0.00001 per share | D | 30000 | $23.05 - $23.05 | $691,500 |
| 2024-01-19 | Viking Therapeutics, Inc. | Rouan Sarah Kathryn
(Director) |
M | Common Stock, par value $0.00001 per share | A | 30000 | $8.32 - $8.32 | $249,600 |
| 2024-01-04 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
S | Common Stock, par value $0.00001 per share | D | 15000 | $17.90 - $17.90 | $268,500 |
| 2024-01-03 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
F | Common Stock, par value $0.00001 per share | D | 62994 | $17.40 - $18.58 | $1,112,463 |
| 2024-01-03 | Viking Therapeutics, Inc. | ZANTE GREG
(Chief Financial Officer) |
A | Common Stock, par value $0.00001 per share | A | 98334 | $0.00 - $0.00 | $0 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |